Netherlands· NL-7e877598697b

Pulmozyme, inhalatievloeistof 1 mg/ml, 2,5 ml

A dornase alfa (desoxyribonuclease) product containing dornase alfa, registered in Netherlands by EU-Pharma B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC R05CB13

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about dornase alfaAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Dornase alfa (desoxyribonuclease) is registered in 11 of 19 countries.

Countries holding a registration under ATC R05CB13 (dornase alfa (desoxyribonuclease)), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
7 of them publish a price we can compare per daily dose

Search dornase alfa (desoxyribonuclease) products by name

Dornase alfa (desoxyribonuclease) · ATC R05CB13

11 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Switzerlandprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: DORNASE ALFA
Manufacturer: EU-Pharma B.V.
Country: Netherlands (NL)
ATC code: R05CB13
ATC class: Dornase alfa (desoxyribonuclease)
Defined daily dose: 2.5 mg, Inhal
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
27368//16734

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for dornase alfa (desoxyribonuclease).

Graded by severity as the source publishes them — 5 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check dornase alfa (desoxyribonuclease) against other medicines How interaction checks work

Dornase alfa (desoxyribonuclease) · interactions on record

5 records

5 moderate

Most severe, free to view

Insulin (human)A10AB01moderate
Insulin (human)A10AC01moderate
Insulin (human)A10AD01moderate
Insulin (human)A10AE01moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dornase alfa (desoxyribonuclease) in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dornase alfa (desoxyribonuclease) products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

Austria · Pulmozyme
Belgium · Pulmozyme
Bulgaria · Пулмозим
Cyprus · Pulmozyme
Czechia · Pulmozyme
Germany · Pulmozyme
Denmark · Pulmozyme
Estonia · Pulmozyme
Spain · Pulmozyme
Finland · Pulmozyme
France · Pulmozyme
United Kingdom (Northern Ireland) · Pulmozyme
Greece · Pulmozyme
Croatia · Pulmozyme Otopina Za Atomizator
Hungary · Pulmozyme
Ireland · Pulmozyme
Iceland · Pulmozyme
Italy · Pulmozyme
Lithuania · Pulmozyme
Luxembourg · Pulmozyme
Latvia · Pulmozyme
Norway · Pulmozyme
Poland · Pulmozyme
Portugal · Pulmozyme
Romania · Pulmozyme
Sweden · Pulmozyme
Slovenia · Pulmozyme
Slovakia · Pulmozyme

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/f79ebe83-a4dd-48ef-8a7d-976cef596d12
GET /v1/drugs/f79ebe83-a4dd-48ef-8a7d-976cef596d12?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Verneveloplossing",
  "route": "Inhalatie",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h16734_smpc.pdf",
  "strength": null,
  "atc_label": "Dornase Alfa (Desoxyribonuclease)",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg27368",
  "excipients": [
    "CALCIUMCHLORIDE 2-WATER (E 509)",
    "NATRIUMCHLORIDE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "DORNASE ALFA"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h27368.pdf",
  "authorised_at": "2002/02/19",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "27368//16734",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about dornase alfa (desoxyribonuclease).

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console